Stereochemistry | ACHIRAL |
Molecular Formula | C7H7N6.Na |
Molecular Weight | 198.1604 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].C1CC2=C(C1)C(=NN2)C3=NN=N[N-]3
InChI
InChIKey=WAEMBJUTNFWNNK-UHFFFAOYSA-N
InChI=1S/C7H7N6.Na/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7;/h1-3H2,(H-,8,9,10,11,12,13);/q-1;+1
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C7H8N6 |
Molecular Weight | 176.1786 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Cmax
AUC
T1/2
Sourcing
PubMed
Patents
Sample Use Guides
In a phase II study MK-0354 was administred daily at dose 2.5g for 4 weeks.
Route of Administration:
Oral
Equilibrium binding of [3H]nicotinic acid was done with membranes (30 μg/assay) from CHO-K1 cells, transfected with GPR109a, and test compound diluted in assay buffer (20 mM HEPES, pH 7.4, 1 mM MgCl2, and 0.01% CHAPS) in a total volume of 200 uL. After 4 h at room temperature, reactions were filtered through Packard Unifilter GF/C plates using a Packard Harvester and washed eight times with 200 μl of ice-cold binding buffer. Nonspecific binding was determined in the presence of 250 μM unlabeled nicotinic acid. Competitive binding assays were performed in the presence of 50 nM [3H]nicotinic acid.